Bemcentinib to be fast-tracked for a phase II trial in the UK as a potential COVID-19 treatment

The ACCORD study is a multicentre, seamless, Phase II adaptive randomisation platform trial to assess the efficacy and safety of multiple candidate agents, the first of which is bemcentinib (an AXL kinase inhibitor), for the treatment of COVID-19 in hospitalised UK NHS patients.


Biospace Inc.